Printer Friendly

United States : ACETO Subsidiary, Rising Pharmaceuticals, Announces Product Launches.

ACETO Corporation, an international company engaged in the development, marketing, sale and distribution of Human Health products, Pharmaceutical Ingredients and Performance Chemicals, announced that Rising Pharmaceuticals, its finished dosage form generics subsidiary, recently launched:

Ramipril Capsules, 1.25mg, 2.5mg, 5mg, and 10mg, an FDA-approved generic version of the reference listed drug, Altace from Pfizer, which is indicated for the treatment of hypertension.

Losartan Potassium Tablets, 25mg and 50mg, an FDA-approved generic version of the reference listed drug, Cozaar from Merck, which is also indicated for the treatment of hypertension.

Losartan Potassium and Hydrochlorothiazide Tablets, 50-12.5mg, 100-12.5mg, and 100-25mg, an FDA-approved generic version of the reference listed drug, Hyzaar from Merck, which is also indicated for the treatment of hypertension.

Pravastatin Tablets, 10mg, 20mg, 40mg, and 80mg, an FDA-approved generic version of the reference listed drug, Pravachol from Bristol-Myers Squibb, which is indicated as an adjunct to diets restricting saturated fats and cholesterol.

Temozolomide Capsules, 5mg, 20mg, 100mg, 140mg, 180mg, and 200mg, an FDA-approved generic version of the reference listed drug Temodar from Schering, which is indicated for the treatment of adult patients with newly diagnosed glioblastoma multiforme.

Zolmitriptan Orally Disintegrating Tablets, 2.5mg and 5mg, an FDA-approved generic version of the reference listed drug Zomig-ZMT from AstraZeneca, which is indicated for the acute treatment of migraines.

The six products launched had combined U.S. sales of approximately $580 million for the 12 months ending May 2017, according to IMS Health.

ACETO Corporation sells generic prescription products and over-the-counter pharmaceutical products under its Rising label to leading wholesalers, chain drug stores, distributors and mass merchandisers, and the launch of the six products above adds to its significant human pharmaceutical franchise. Rising Pharmaceuticals has built a commercial portfolio of over 120 products currently in the U.S. market. It also has a development portfolio of more than 50 ANDAs filed with the FDA or pending launch, representing over $7.2 billion in addressable market value, using recent IMS sales data.

[c] 2017 Al Bawaba (Albawaba.com) Provided by SyndiGate Media Inc. ( Syndigate.info ).

COPYRIGHT 2017 SyndiGate Media Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Mena Report
Date:Jul 22, 2017
Words:344
Previous Article:United States : Corker Applauds Trump Administration Commitment to completely Annihilate Isis.
Next Article:United States : Evoqua Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters